Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Trial Details

NCT ID

NCT06906341

Phase

PHASE2

Sponsor

Corcept Therapeutics

Status

RECRUITING

Cancer Type

Ovarian Cancer

Interventions

• Relacorilant 150 mg once daily (QD)
• Nab-paclitaxel 80 mg/m^2
• Bevacizumab 10 mg/kg

Locations (sample)

• Birmingham, Alabama, United States|33.52066,-86.80249
• Palo Alto, California, United States|37.44188,-122.14302
• San Francisco, California, United States|37.77493,-122.41942
• Fort Myers, Florida, United States|26.62168,-81.84059
• Miami Beach, Florida, United States|25.79065,-80.13005

Key Eligibility Criteria

• Arms A and B
• Histologic diagnosis of epithelial ovarian, primary peritoneal, or fallopian-tube carcinoma
• Arm A Only: Platinum-resistant disease
• Arm B Only: Platinum-sensitive disease who had progression while receiving treatment with a poly(ADP-ribose) polymerase (PARP) inhibitor

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.